|
University
of Calgary led study suggests ancient viral protein may be
part of multiple sclerosis development
Medical Update Memo
October 12, 2004
Summary
What sets off the destruction within the central nervous system
during the multiple sclerosis process remains a central question.
A recently published study suggests that a protein called
syncytin, which is produced by a virus that has existed within
human genetic material for more than 20 million years, may
play a key role in the attack on the myelin protective covering
of the brain and spinal cord and on myelin-making cells themselves.
Dr. Christopher Power, and MS Society studentship recipient
Joseph Antony, University of Calgary, and colleagues report
the findings in the October 2004 issue of Nature Neurology.
The overall work was supported by the Multiple Sclerosis
Society of Canada. Working with cell cultures and animal
models, they found an anti-oxidant called ferulic acid reduced
the death of myelin-making cells. This work provides more
insights into how the disease progresses and points to possible
new approaches to treatment.
Details
What triggers the damaging attack on the myelin protecting
covering of the brain and spinal cord and on myelin-making
cells (oligodendrocytes) is still unknown. The unpredictable
attacks and numerous symptoms result from an inflammatory
process that arises within the immune system. Many suggest
that MS results through an autoimmune process in which exposure
to an external virus or bacterium may trigger the disease
process, possibly through molecular mimicry. A protein in
a virus or bacterium may be similar to a protein within the
body, thus triggering the autoimmune response. Within the
immune system, T cells and other immune cells are thought
to lead the attack on myelin and myelin-making cells.
A recently published study by an international
team of researchers including Dr. Christopher Power and Joseph
Antony, University of Calgary, suggests that a protein called
syncytin may play a key role in this attack (Nature Neurology,
Vol. 7, No. 10, October 2004). The international research group
is from the University of Calgary, University of Alberta, University
of Kentucky, University of Oxford and Ecole Normale Superieure
de Lyon, France. Mr. Antony holds a research studentship from
the Multiple Sclerosis Society of Canada. The overall research
was supported by the MS Society of Canada and the Canadian
Institutes of Health Research.
Syncytin is produced by the body from a
virus embedded in humans during evolution more than 20 million
years ago. It is known to have an important role in the developing
placenta, but a further role in the central nervous system
has not been identified until now.
The researchers found that levels of syncytin
were significantly higher in brain tissue samples from three
people with MS, compared to tissue samples from people with
Alzheimer disease, HIV encephalitis or without a neurological
condition. Syncytin expression was increased specifically in
areas where myelin-damage was actively occurring.
Syncytin was shown to induce the production
of oxidants, molecules that can be toxic to certain cells.
The researchers found that adding syncytin to cell cultures
of myelin-making cells resulted in the death of these cells.
They also found they could prevent this toxicity by adding
an anti-oxidant called ferulic acid, an anti-inflammatory drug
or by substances that inhibit nitric oxide production.
They also worked with mice to find out if
syncytin can cause demyelination in an animal model. Mice injected
with a syncytin-producing virus resulted in myelin damage and
impaired motor function. When mice were given ferulic acid,
the treatment markedly reduced the death of myelin-making cells
and motor function improved in the mice.
This study suggests that syncytin may be
involved in the process of active myelin destruction or that
it may block attempts by myelin-making cells to produce new
myelin. It also points to possible uses for ferulic acid or
similar substances in blocking myelin damage or in boosting
remyelination.
In an accompanying editorial, Drs. Mark
Mattson and Dennis Taub, National Institute on Aging, Baltimore,
noted that although the study found an association between
syncytin and the inflammatory processes that occur in MS, it
did not establish a role for the protein in the development
of the disease. Further studies will be required to confirm
these interesting findings which could open new avenues of
investigation into the underlying disease process and possible
new treatment approaches.
ASK MS Information System Code: 2.7.i
National Research Department
National Communications & Government Relations Department

Click
here to view or print this bulletin in its
original format.


Disclaimer
The Multiple Sclerosis Society of Canada is an independent,
voluntary health agency and does not approve, endorse or
recommend any specific product or therapy but provides information
to assist individuals in making their own decisions.
|